575 Results (Page 23 of 23)
China Markets Research Reports
China Castrate Resistant Prostate Cancer Therapeutics Market Analysis
China Castrate Resistant Prostate Cancer Therapeutics Market valued at $28 Mn in 2022, projected to reach $450 Mn by 2030 with a 6.10% CAGR. The key drivers of this market are the rapidly aging population in China, with an increasing risk of prostate cancer, coupled with the evolving healthcare system reforms, increased government investment, and accessibility of innovative CRPC therapies by multinational pharmaceutical companies. The China Castrate Resistant Prostate Cancer Therapeutics Market encompasses various players across different segments, including Pfizer, Johnson & Johnson, Roche, Bayer, AstraZeneca, Sanofi, BeiGene, Innovent Biopharmaceuticals, Shanghai Junshi Biosciences, Henlius Biotech, etc, among various others.
China Brain Cancer Therapeutics Market
China Brain Cancer Therapeutics Market valued at $185 Mn in 2022, projected to reach $461 Mn by 2030 with a 12.1% CAGR. The anticipated increase in cases of brain cancer, particularly glioblastoma multiforme, is expected to markedly boost the need for brain cancer therapeutics, shaping the overall market landscape significantly. The top leading pharmaceutical companies currently operating in the market are Innovent, Hutchison MediPharmaceuticals, China Resources Pharmaceutical Group (CRPG), BeiGene, Hansoh Pharmaceutical Group Co., Zhejiang Hisun Pharmaceutical Co., Yishuntai Pharmaceuticals Group Co., Jiangsu Hengrui Medicine Co., Shanghai Junsun Science & Technology Co. and Guangzhou Institute of Biopharmaceutical Technology (GIBT).
China Herbal Supplements Market Report
The China Herbal Supplements Market was valued at $422.84 Mn in 2023 and is predicted to grow at a CAGR of 7.7% from 2023 to 2030, to $710.69 Mn by 2030. The key drivers of this industry include traditional medicine influence, health and wellness trends, and an aging population. The industry is primarily dominated by players such as Ningbo Herb, KPC Herbs, Herbalife, and Kangmei Pharmaceutical Co., Ltd among others.
China Clinical Nutrition for Chronic Kidney Diseases Market Analysis
China Clinical Nutrition for Chronic Kidney Diseases Market was valued at $126.20 Mn in 2023 and is predicted to grow at a CAGR of 7.53% from 2023 to 2030, to $209.80 Mn by 2030. The key drivers of this industry include the high prevalence of CKD, increasing awareness and education, and technological advancements. The industry is primarily dominated by Abbott Nutrition, Pfizer Inc., Bayer AG, and Nestlé Health Science among others.
China Brugada Syndrome Market Analysis
The China Brugada Syndrome Market was valued at $96.5 Mn in 2023 and is predicted to grow at a CAGR of 9.3% from 2023 to 2030, to $179.8 Mn by 2030. The key drivers of the market include growing prevalence of cardiovascular diseases, increasing awareness and diagnosis, and advancements in genetic testing. The prominent players of the China Brugada Syndrome Market are AstraZeneca, Abbott, Bayer, Merck, and Sanofi, among others.
China Blood Disorder Therapeutics Market
China Blood Disorder Therapeutics Market valued at $1.077 Bn in 2022, projected to reach $2.145 Bn by 2030 with a 9% CAGR. The key drivers of the China Blood Disorder Therapeutics Market include the growing prevalence of blood illnesses associated with an aging population and industrialization-related factors, coupled with a government push for domestic innovation, increased spending on healthcare, and rising disposable incomes. The China Blood Disorder Therapeutics Market encompasses various players across different segments, including Takeda, Roche, Bayer, Pfizer, Novartis, Johnson & Johnson, BeiGene, Innovent Biologics, Simcere, Shanghai Junshi Biosciences, etc, among various others.
China Dental Endodontics Market Analysis
China Dental Endodontics Market was valued at $140.70 Mn in 2023 and is predicted to grow at a CAGR of 5.8% from 2023 to 2030, to $208.70 Mn by 2030. The key drivers of this industry include growing demand for cosmetic dentistry, increasing dental awareness, and expansion of dental infrastructure. The industry is primarily dominated by Coltene, Dentsply Sirona, FKG Dentaire, and Ultradent Products among others.
China Clinical Nutrition Market Analysis
The China Clinical Nutrition Market was valued at $2465.5 Mn in 2023 and is projected to grow at a CAGR of 6.84% from 2023 to 2023, to $3917.8 Mn by 2030. The key drivers of this industry are increasing prevalence of chronic diseases and metabolic disorders, aging population, increasing awareness of the importance of nutrition for health, product innovations and technological advancements, government initiatives and rising healthcare expenditure, rising incidence of malnutrition especially in paediatric patients which has contributed to market growth. The industry is primarily dominated by players such as CSPC Pharmaceuticals Group, Fancl Corporation, Health Food Company, Amway, Pfizer, Bayer among others.
China Breast Pump Market Report
The China Breast Pump Market was valued at $236.3 Mn in 2023 and is predicted to grow at a CAGR of 10.1% from 2023 to 2030, to $463.5 Mn by 2030. The key drivers of the market include the rising female workforce, technological innovations, and growing consumer awareness. The prominent players in the China Breast Pump Market are Medela, Philips Avent, Ameda AG, Ardo Medical AG, Pigeon Corporation, Lansinoh Laboratories, Tommee Tippe.
China Congestive Heart Failure Therapeutics Market Analysis
The China Congestive Heart Failure Therapeutics Market is anticipated to experience a growth from $0.828 Bn in 2022 to $1.455 Bn by 2030, with a CAGR of 7.3% during the forecast period of 2022-2030. The market in China is driven by a confluence of various factors including a rapidly aging population, urbanization-induced lifestyle changes that increase the incidence of cardiovascular risk factors, and ongoing efforts to develop healthcare infrastructure, all of which contribute to increased demand for therapeutics. The China Congestive Heart Failure Therapeutics Market is dominated by key players from various therapeutic segments, including AstraZeneca, Bayer, Novartis, Eli Lilly, Merck, Sanofi, Jiangsu Hengrui Medicine, Shanghai Fosun Pharmaceutical, Shenzhen Chipscreen Biosciences, Guangzhou Kangchao Pharmaceutical, among others.
China Biosensors Market Analysis
The China Biosensors Market was valued at $2323.2 Mn in 2023 and is predicted to grow at a CAGR of 9.5% from 2023 to 2030, to $4385.1 Mn by 2030. The key drivers of the market include increasing burden of chronic diseases, technological advancements, and growing demand for Point-of-Care (POC) testing. The prominent players of the China Biosensors Market are Abbott Laboratories, Biosensors International, Bio-Rad International, DowDuPont, and Masimo Corporation, among others.
China Digital Biomarkers Market Analysis
China Digital Biomarkers Market was valued at $233.12 Mn in 2023 and is predicted to grow at a CAGR of 23.8% from 2023 to 2030, to $1,039.03 Mn by 2030. The key drivers of this industry include the rising burden of chronic diseases, government initiatives, and a focus on personalized medicine. The industry is primarily dominated by ActiGraph LLC, AliveCor Inc., Koneksa, and Altoida Inc. among others.
China Cancer Induced Bone Disease Therapeutics Market
China Cancer Induced Bone Disease Therapeutics Market valued at $105 Mn in 2022, projected to reach $184 Mn by 2030 with a 7.3% CAGR. The key drivers of this industry include the rising incidence of cancers, government initiatives, and untapped market potential. The industry is primarily dominated by players such as Siemen, Hengrui, Shanghai Pharma, Johnson & Johnson, Novartis, and Amgen among others.
China Medication Access Programs Market Analysis
The China Medication Access Programs Market was valued at $441.3 Mn in 2023 and is predicted to grow at a CAGR of 16.1% from 2023 to 2030, to $1254.7 Mn by 2030. The key drivers of this industry include rising healthcare spending, growing chronic disease burden, and government initiatives. The industry is primarily dominated by players such as Gilead Sciences, Takeda Pharmaceuticals, Pfizer, and Novartis among others.
China Dental Consumables Market Analysis
The China Dental Consumables Market was valued at $2717.1 Mn in 2023 and is projected to grow at a CAGR of 9.5% from 2023 to 2023, to $5128.6 Mn by 2030. The key drivers of this industry growing dental care needs, technological advancements, expanding dental infrastructure, increasing disposable incomes, public health initiatives, dental tourism, rising consumption of sugary and starchy foods, rise in unhealthy eating habits due to rising urbanization, and changing living standards. The industry is primarily dominated by players such as Thommen Medical AG, Nobel Biocare Services AG, Dentsply Sirona, Colgate Palmolive, Align Technology, 3M, and Carestream Dental among others.
China Physiotherapy Equipment Market Analysis
The China Physiotherapy Equipment Market was valued at $1,680.09 Mn in 2023 and is predicted to grow at a CAGR of 8.7% from 2023 to 2030, to $3,012.59 Mn by 2030. The key drivers of this industry include the rising prevalence of chronic diseases, expanding geriatric population, and advancements in technology. The key players in the industry are HMS Medical Systems, Wego Medical, WNQ, and Orient among others.
China Cardiac Resynchronization Therapy Market
China Cardiac Resynchronization Therapy Market was valued at $386 Mn in 2022 and is estimated to reach $639 Mn in 2030, exhibiting a CAGR of 6.5% during the forecast period. The global surge in heart failure cases, driven by aging populations and lifestyle-related cardiovascular diseases, is a significant catalyst contributing to the expansion of the Cardiac Resynchronization Therapy (CRT) market. Currently, major contributors to this market include companies such as Medtronic, Boston Scientific, Abbott, Siemens Healthineers, MicroPort Apsara, Lepu Medical Technology Co., Beijing Easywell Medical Device Co., Shenzhen Lepu Heart Valve Technology Co., Terumo Corporation, and Osram Health.
China Patient Adherence Programs Market Analysis
The China Patient Adherence Programs Market was valued at $1041.5 Mn in 2023 and is predicted to grow at a CAGR of 19.5% from 2023 to 2030, to $3624.4 Mn by 2030. The key drivers of the market include increasing non-adherence, rising chronic conditions, and an aging population. The prominent players of the China Patient Adherence Programs Market are, among others
China Cardiac Arrhythmia Therapeutics Market
China Cardiac Arrhythmia Therapeutics Market valued at $579 Mn in 2022, projected to reach $1,017 Mn by 2030 with a 7.3% CAGR. The key drivers of this industry include a surge in the prevalence of cardiac arrhythmias, government initiatives, and technological advancements. The industry is primarily dominated by players such as Abbott, MicroPort, Lepu Medical Technologies, Boston Scientific, Terumo, and Merck among others.
China Kidney Cancer Therapeutics Market Analysis
The China Kidney Cancer Therapeutics Market was valued at $505.64 Mn in 2023 and is predicted to grow at a CAGR of 6.36% from 2023 to 2030, to $788.55 Mn by 2030. China Kidney Cancer Therapeutics Market is growing due to Increased Incidence of Kidney Diseases, Demand for Immunotherapies, Government initiatives, and funding. The industry is primarily dominated by players such as Pfizer Inc (U.S.), AstraZeneca (U.K.), Bristol-Myers Squibb Company (U.S.), Dr. Reddy's Laboratories Ltd (India), Sun Pharmaceutical Industries Ltd (India) and Novartis AG (Switzerland).
China LASIK Surgery Market Analysis
China LASIK Surgery Market was valued at $283.77 Mn in 2023 and is predicted to grow at a CAGR of 6.71% from 2023 to 2030, to $447.09 Mn by 2030. The key drivers of this industry include the rising prevalence of myopia, growing disposable income, and technological advancements. The industry is primarily dominated by Johnson & Johnson Vision, Zeimer Ophthalmic System AG, Abbott, and Carl ZEISS AG, among others.
China Medical Digital Imaging System Market Analysis
The China Medical Digital Imaging System Market was valued at $2451.81 Mn in 2023 and is predicted to grow at a CAGR of 9.7% from 2023 to 2030, to $4687.42 Mn by 2030. The key drivers of this industry include increasing healthcare spending, rising chronic disease, and the aging population. The industry is primarily dominated by players such as Siemens Healthineers, GE Healthcare, Philips Healthcare, and Canon Medical Systems among others.
China Hemodialysis Vascular Grafts Market Analysis
China Hemodialysis Vascular Grafts Market was valued at $16.84 Bn in 2023 and is predicted to grow at a CAGR of 6.6% from 2023 to 2030, to $26.34 Bn by 2030. The key drivers of this industry include the rising prevalence of end-stage renal disease (ESRD), government initiatives, and investment in healthcare, technological advancements. The industry is primarily dominated by W. L. Gore, C. R. Bard, Vascudyne, and LeMaitre among others.
China Breastfeeding Accessories Market Analysis
China Breastfeeding Accessories Market was valued at $201.77 Mn in 2023 and is predicted to grow at a CAGR of 8.30% from 2023 to 2030, to $352.58 Mn by 2030. The key drivers of this industry include a high breastfeeding rate, government support and initiatives, and growth of e-commerce. The industry is primarily dominated by Medala, Elvie, Willow Innovations, and Koninklijke Philips among others.
China Hospital Market Analysis
The China Hospital Market was valued at $442.09 Bn in 2023 and is predicted to grow at a CAGR of 9.1% from 2023 to 2030, to $813.37 Bn by 2030. The key drivers of this industry are rise in geriatric population, increase in healthcare awareness, and government investment. The key players in the industry are United Family Healthcare, Aier Eye Hospital Group, Rici Healthcare Holdings, and Hua Sheng Group among others.
